A1LN34 Total Debt vs. Shares Outstanding
| A1LN34 Stock | BRL 73.85 0.35 0.48% |
For A1LN34 profitability analysis, we use financial ratios and fundamental drivers that measure the ability of A1LN34 to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well A1LN34 utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between A1LN34's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of A1LN34 over time as well as its relative position and ranking within its peers.
A1LN34 |
A1LN34 Shares Outstanding vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining A1LN34's current stock value. Our valuation model uses many indicators to compare A1LN34 value to that of its competitors to determine the firm's financial worth. A1LN34 is the top company in total debt category among its peers. It also is number one stock in shares outstanding category among its peers creating about 3.09 of Shares Outstanding per Total Debt. Comparative valuation analysis is a catch-all model that can be used if you cannot value A1LN34 by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for A1LN34's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.A1LN34 Total Debt vs. Competition
A1LN34 is the top company in total debt category among its peers. Total debt of Biotechnology industry is presently estimated at about 1.88 Trillion. A1LN34 adds roughly 761.07 Million in total debt claiming only tiny portion of stocks in Biotechnology industry.
A1LN34 Shares Outstanding vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
A1LN34 |
| = | 761.07 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
A1LN34 |
| = | 2.35 B |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
A1LN34 Shares Outstanding Comparison
A1LN34 is currently under evaluation in shares outstanding category among its peers.
A1LN34 Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in A1LN34, profitability is also one of the essential criteria for including it into their portfolios because, without profit, A1LN34 will eventually generate negative long term returns. The profitability progress is the general direction of A1LN34's change in net profit over the period of time. It can combine multiple indicators of A1LN34, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. ALNYLAM PHARDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 1453 people.
A1LN34 Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on A1LN34. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of A1LN34 position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the A1LN34's important profitability drivers and their relationship over time.
Use A1LN34 in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if A1LN34 position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in A1LN34 will appreciate offsetting losses from the drop in the long position's value.A1LN34 Pair Trading
A1LN34 Pair Trading Analysis
The ability to find closely correlated positions to A1LN34 could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace A1LN34 when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back A1LN34 - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling A1LN34 to buy it.
The correlation of A1LN34 is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as A1LN34 moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if A1LN34 moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for A1LN34 can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your A1LN34 position
In addition to having A1LN34 in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in A1LN34 Stock
To fully project A1LN34's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of A1LN34 at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include A1LN34's income statement, its balance sheet, and the statement of cash flows.